Who pays, and for what?
A prospective client needs an appropriate clinical evaluation, a safe treatment decision, truthful risks and pricing, and a plan for adverse events. A marketer or unlicensed founder cannot make those clinical judgments.
Separate a legally reviewed cash-pay model from any insured medical-service model. Include licensed clinicians, medical direction, sterile product sourcing, facilities, malpractice coverage, documentation, waste, emergency capability, refunds, and capacity.
What the demand evidence says
FDA warns that compounded drugs are not FDA-approved and that poor compounding can cause serious harm. That supports a safety gate, not a finding that an IV menu is clinically appropriate or profitable.
Employment projections describe occupations, not customer spending, business-owner income, or guaranteed local demand. Test the service with actual buyers and quotes in your market.
What drives the startup cost
- State corporate-practice and facility ownership review
- Qualified prescriber, nursing scope, medical direction, protocols, and supervision
- Licensed pharmacy or lawful manufacturer source, storage, tracking, and recall process
- Clinical records, privacy, emergency response, insurance, and medical waste
Gates to clear before selling
- Get written state-specific legal and clinical review before spending on a location, mobile van, or treatment menu.
- Do not prescribe, administer, compound, advertise clinical claims, or take clinical intake through Academy tools.
- Use licensed professionals and approved systems for clinical records and any protected health information; education alone is not HIPAA compliance.
- Verify sourcing, labeling, storage, contraindication screening, adverse-event response, and waste handling under the responsible professional.
- Do not promise detoxification, cure, athletic performance, or insurer payment without competent evidence and applicable authority.
Where to test demand first
- Interview qualified clinicians and potential referral partners about unmet needs without soliciting treatment.
- Model a narrow licensed service and an adverse-event scenario with a clinician and healthcare attorney.
- Pilot only after permits, professional authority, clinical policies, privacy systems, and insurance are active.
Research sources
- FDA: human drug compoundingCompounded-drug status, limitations, and safety context. · Research check: 2026-09-22
- FDA: compounding questions and answersCompounded drugs are not FDA-approved and can pose quality risks. · Research check: 2026-09-22
- HHS: covered entities and business associatesHIPAA role and business-associate boundary for actual clinical operations. · Research check: 2026-09-22
